- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
PET/CT boosts classification of incidental adrenal masses
In what is possibly the largest study of its kind, Harvard University researchers have shown that PET/CT can reliably tell whether unsuspected adrenal lesions discovered while managing oncologic patients are benign or malignant.
In what is possibly the largest study of its kind, Harvard University researchers have shown that PET/CT can reliably tell whether unsuspected adrenal lesions discovered while managing oncologic patients are benign or malignant.
Incidental adrenal lesions in patients with cancer require accurate characterization because their status can significantly affect staging, therapy, and prognosis. Several imaging tests are available to offer a helping hand, including contrast/noncontrast CT and MRI. None, however, has proven conclusive.
A 2006 Massachusetts General Hospital study of 38 patients found PET/CT to be sensitive and specific for the characterization of incidental adrenal lesions (Blake MA, Slattery JM, Kalra MK. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy-initial experience. Radiology 2006;238(3):970-977). The results encouraged an investigative group led by Dr. Giles W. L. Boland, an associate professor of radiology at Mass General, to validate the findings in a larger cohort of patients.
Between October 2004 and March 2007, Boland and colleagues evaluated 150 patients with various malignancies, including lymphoma and lung, head and neck, and colorectal cancer. All patients underwent noncontrast PET/CT and a follow-up CT scan six months later. The researchers confirmed that PET/CT was highly effective for differentiating benign from malignant adrenal disease in this patient population. Based on a qualitative analysis, PET/CT yielded sensitivity, specificity, accuracy, and positive and negative predictive values for characterization of benign adrenal "incidentalomas" of 100%, 97%, 98%, 87%, and 100%, respectively.
Boland cautioned the study had several limitations, including the retrospective nature of the sample. He called for careful consideration of many other criteria, including the Hounsfield unit and standardized uptake value measurements, adrenal wash-outs, and lesion size assessments. But the findings showed a way forward, he said.
"PET/CT is indeed an accurate test," Boland said.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
